Engex, Inc. is an AMEX listed security that has been trading in a range between $7.16 and $9.70 over the past year. With 1,465,840 shares outstanding, a recent price of $8.85 gives a total market capitalization of $12,972,685. While there are certainly larger companies, Engex, Inc. has definitely earned its place in the pack. Last year, Engex, Inc. created $-2.42 in earnings for every share outstanding.
Engex, Inc. is currently priced by the market at 0.00 times last year’s earnings. Many trading multiples around the world are quite attractive these days, but don’t be fooled. A Price to Earnings ratio of 0 simply means that the security didn’t make any money last year.
With a share price under $50 a share and earnings per share below $1 a share, Engex, Inc. is unlikely to be an interesting value proposition.
Showing posts with label Biotechnology. Show all posts
Showing posts with label Biotechnology. Show all posts
Monday, July 16, 2007
Monday, July 9, 2007
Genzyme Corp.
Genzyme Corp. is among the world’s largest Biotechnology sector businesses in the world. Genzyme Corp.’s employees generate $40.4M in profits on $3.339B of revenue. Global output in the Biotechnology business will likely rise substantially over the next 10 years. Long-term economic growth may lift all boats, but Genzyme Corp. is determined to remain a market leader. Sectoral leadership in the Biotechnology segment takes dedication and consistency, but management seeks out-sized growth.
Genzyme Corp.’s ticker symbol GENZ has recently been trading near $65.64 a share. The Genzyme Corp. corporate headquarters in Cambridge MA predicts Biotechnology profits will satisfy shareholders in search of risk-appropriate returns.
The significance of market volume is sometimes ignored, but with a total market capitalization of $17.332B ensures sufficient liquidity. With a beta of 0.81, the company is less volatile than the market as a whole. When the average equity moves lower, Genzyme Corp. moves less aggressively.
Genzyme Corp.’s ticker symbol GENZ has recently been trading near $65.64 a share. The Genzyme Corp. corporate headquarters in Cambridge MA predicts Biotechnology profits will satisfy shareholders in search of risk-appropriate returns.
The significance of market volume is sometimes ignored, but with a total market capitalization of $17.332B ensures sufficient liquidity. With a beta of 0.81, the company is less volatile than the market as a whole. When the average equity moves lower, Genzyme Corp. moves less aggressively.
Genzyme Corp.
Genzyme Corp. is among the world’s largest Biotechnology sector businesses in the world. Genzyme Corp.’s employees generate $40.4M in profits on $3.339B of revenue. Global output in the Biotechnology business will likely rise substantially over the next 10 years. Long-term economic growth may lift all boats, but Genzyme Corp. is determined to remain a market leader. Sectoral leadership in the Biotechnology segment takes dedication and consistency, but management seeks out-sized growth.
Genzyme Corp.’s ticker symbol GENZ has recently been trading near $65.64 a share. The Genzyme Corp. corporate headquarters in Cambridge MA predicts Biotechnology profits will satisfy shareholders in search of risk-appropriate returns.
The significance of market volume is sometimes ignored, but with a total market capitalization of $17.332B ensures sufficient liquidity. With a beta of 0.81, the company is less volatile than the market as a whole. When the average equity moves lower, Genzyme Corp. moves less aggressively.
Genzyme Corp.’s ticker symbol GENZ has recently been trading near $65.64 a share. The Genzyme Corp. corporate headquarters in Cambridge MA predicts Biotechnology profits will satisfy shareholders in search of risk-appropriate returns.
The significance of market volume is sometimes ignored, but with a total market capitalization of $17.332B ensures sufficient liquidity. With a beta of 0.81, the company is less volatile than the market as a whole. When the average equity moves lower, Genzyme Corp. moves less aggressively.
Tuesday, July 3, 2007
Celgene Corp.
Celgene Corp. is among the world’s largest Biotechnology sector businesses in the world. Celgene Corp.’s employees generate $110.4M in profits on $1.010B of revenue. Global output in the Biotechnology business will likely rise substantially over the next 10 years. Long-term economic growth may lift all boats, but Celgene Corp. is determined to remain a market leader. Sectoral leadership in the Biotechnology segment takes dedication and consistency, but management seeks out-sized growth.
Celgene Corp.’s ticker symbol CELG has recently been trading near $58.05 a share. The Celgene Corp. corporate headquarters in Summit, NJ predicts Biotechnology profits will satisfy shareholders in search of risk-appropriate returns.
The significance of market volume is sometimes ignored, but with a total market capitalization of $22.052B ensures sufficient liquidity. With a beta of 0.44, the company is less volatile than the market as a whole. When the average equity moves lower, Celgene Corp. moves less aggressively.
Celgene Corp.’s ticker symbol CELG has recently been trading near $58.05 a share. The Celgene Corp. corporate headquarters in Summit, NJ predicts Biotechnology profits will satisfy shareholders in search of risk-appropriate returns.
The significance of market volume is sometimes ignored, but with a total market capitalization of $22.052B ensures sufficient liquidity. With a beta of 0.44, the company is less volatile than the market as a whole. When the average equity moves lower, Celgene Corp. moves less aggressively.
BIOGEN IDEC Inc.
BIOGEN IDEC Inc. is among the world’s largest Biotechnology sector businesses in the world. BIOGEN IDEC Inc.’s employees generate $226.0M in profits on $1.953B of revenue. Global output in the Biotechnology business will likely rise substantially over the next 10 years. Long-term economic growth may lift all boats, but BIOGEN IDEC Inc. is determined to remain a market leader. Sectoral leadership in the Biotechnology segment takes dedication and consistency, but management seeks out-sized growth.
BIOGEN IDEC Inc.’s ticker symbol BIIB has recently been trading near $53.43 a share. The BIOGEN IDEC Inc. corporate headquarters in Cambridge, MA predicts Biotechnology profits will satisfy shareholders in search of risk-appropriate returns.
The significance of market volume is sometimes ignored, but with a total market capitalization of $18.282B ensures sufficient liquidity. With a beta of 1.09, the company is more volatile than the market as a whole. When the average equity moves higher, BIOGEN IDEC Inc. moves more aggressively.
BIOGEN IDEC Inc.’s ticker symbol BIIB has recently been trading near $53.43 a share. The BIOGEN IDEC Inc. corporate headquarters in Cambridge, MA predicts Biotechnology profits will satisfy shareholders in search of risk-appropriate returns.
The significance of market volume is sometimes ignored, but with a total market capitalization of $18.282B ensures sufficient liquidity. With a beta of 1.09, the company is more volatile than the market as a whole. When the average equity moves higher, BIOGEN IDEC Inc. moves more aggressively.
Subscribe to:
Posts (Atom)
